m+Medelevator.RU
← Поиск публикаций
ACS omega · 2025

Novel Cyanoacrylamides Incorporating Sulfamethoxazole as Potential Anticancer Agents: DNA Interaction, Apoptotic Induction, and S‑Phase Cell Cycle Arrest in Colon Cancer Cells.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Ragheb Mohamed A, Salem Mostafa E, Ali Mona M, Abdelhamid Ismail A, Raza Nadeem, Soliman Marwa H

Аннотация

In the current study, five novel cyanoacrylamides incorporating sulfamethoxazole (5-9) were designed and synthesized as potential candidates for anticancer therapy. The antitumor potential of the synthesized compounds was screened against HCT116, MDA-MB-231, and A549 human tumor cells. Compound 9, incorporating the 4-(piperidin-1-yl)-phenyl moiety, was more effective than 5-fluorouracil against the three cell lines. The shape of colon cancer cells was examined by scanning electron microscope (SEM). Compound 9 could effectively induce HCT116 apoptosis through the remarkable upregulation of Bax and caspase-3 and the downregulation of Bcl2 and survivin. It can also inhibit HCT116 cell cycle progression at the S phase and cell migration, as it significantly downregulates cyclin A1 and upregulates CDH1, respectively. According to UV-vis and EB-displacement measurements, compound 9 could interact with CT-DNA in a mild intercalative way. DNA fragmentation propensities of compound 9 were examined on pBR322 plasmid DNA using gel electrophoresis, revealing that compound 9 exhibited remarkable photofragmentation activity. Moreover, the molecular docking supported that compound 9 had good binding affinities toward the active sites of key proteins implicated in carcinogenesis and metastasis. In conclusion, compound 9 is presented as a remarkable molecule for the development of novel anticancer drugs.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты